News Detail

08 Jul 2019 13:28:00
Report on the results of the sale of warrants offered to existing common shareholders (F53-5)(Edit No.1)
Full Detailed News
Download Full Detailed News
                The results of the sale of Warrants/TSR (F53-5)
Report date of securities allocation     : 08-Jul-2019

Type of offered securities

Offered to

Existing common shareholders
Number of offered warrants (units)       : 182,222,222
Warrant trading symbol                   : DOD-W1
Name of warrant                          : Warrants to Purchase Ordinary Shares 
of DOD Biotech Public Company Limited No. 1
Offering price (baht per unit)           : 0.10
Allocation date                          : 08-Jul-2019
Number of allotted/subscribed warrants   : 182,219,263
Number of remaining warrants (unit)      : 2,959
The company will deal with the remaining : The company will cancel the remaining
 warrants, showing the remaining rights.
 warrants as follows

Remark (Update)                          :
The Warrant Holders shall be entitled to exercise their rights to purchase 
ordinary shares on the last business day of May and November throughout the term
of the Warrants each year. The First Exercise Date is Friday November 29, 2019
and the Last Exercise Date is the date that the Warrants are valid for 2 years
from the Issuance Date, which is on July 7, 2021. ("Last Exercise")

Authorized to sign on behalf of the      : Mr. Wutichai  Anantakul
Position                                 : Director

Miss  Suwarin  Konthong

This announcement was prepared and disseminated by listed company or issuer 
through the electronic system which is provided for the purpose of dissemination
of the information and related documents of listed company or issuer to the
Stock Exchange of Thailand only.  The Stock Exchange of Thailand has   no
responsibility for the correctness and completeness of any statements, figures,
reports or opinions contained in this announcement, and has no liability for any
losses and damages in any cases.  In case you have any inquiries or
clarification regarding this announcement, please directly contact listed
company or issuer who made this announcement.